Purdue Pharma and Sacklers Agree to New $7.4 Billion Opioid Settlement

In a significant legal development, a $7.4 billion settlement between Purdue Pharma and U.S. states and territories has been ratified, linked to the company's controversial opioid marketing practices.

The agreement, which was legally filed in March, emerged following discussions between Purdue, state attorneys general, and other involved parties. Once finalized, the funds are slated for distribution over a 15-year period.

New York Attorney General Letitia James highlighted the settlement's role in holding the Sackler family accountable, denoting their involvement in the opioid crisis through inadequate oversight of the company’s practices.

Under the new terms, the Sackler family, Purdue Pharma’s owners, are expected to contribute a substantial portion of the total settlement amount, which could reach $7 billion.

Significantly, the revised agreement allows individuals to maintain the right to pursue the Sacklers in civil court, should they choose not to accept the legal releases specified in this settlement.

The Sackler family has persistently maintained their innocence, denying any unlawful actions or misconduct.

Although NPR attempted to contact the Sackler family, no official comment has been received at the time of reporting.

Plaintiffs’ attorneys, who have been engaged in protracted litigation against Purdue and the Sacklers, have expressed approval of the new settlement, noting the collective agreement among all eligible states and territories.

The proposed settlement promises to provide over $7 billion, potentially aiding numerous communities affected by the opioid epidemic.

A federal bankruptcy court must still approve the settlement, but experts believe this version is likely to gain acceptance from both the judicial system and the U.S. Justice Department.

The U.S. DOJ's bankruptcy monitoring arm previously contested prior settlement proposals, but the newly revised terms seem to have quelled earlier objections.

If this agreement is finalized, it will add to an already substantial total of over $50 billion paid by various companies involved in opioid manufacturing, distribution, and retail sales amid the escalating opioid crisis.